NCT06135727

Screening Protocol

Name: Clinical Trial NCT06135727
Creator: Topcon Corporation
Keywords: Glaucoma, Maestro2 OCT, device, clinical trial, United States of America

Data Collection for Development of Topcon Health Score

Topcon Corporation·ClinicalTrials.gov·device·Device trialEnrolling by invitation

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Glaucoma
Drug/Device/Intervention: Maestro2 OCT
Study type: Interventional
Intervention type: device

Sponsor & location

Primary sponsor: Topcon Corporation
Location: La Jolla, United States of America

Timeline & enrollment

Phase: N/A
Start date: Nov 07, 2023
End date: Dec 01, 2025
Enrollment: 505 participants

Primary outcome

RNFL and GCL thickness

Summary

The objective of this study is to collect data for the development and validation a screening process using aggregate data.  In this study, data collection will encompass both retrospective and prospective approaches across multiple sites in the United States.

ICD-10 classifications

GlaucomaGlaucomaOther glaucomaGlaucoma, unspecifiedGlaucoma in diseases classified elsewhere

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06135727
Type: Device Trial

About this record

Access comprehensive clinical trial information for NCT06135727 through Pure Global AI's free database. This phase not specified trial is sponsored by Topcon Corporation and is currently Enrolling by invitation. The study focuses on Glaucoma. Target enrollment is 505 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.